Transforming cancer journeys through disruptive innovations ——Drug-resistant & metastatic cancer: AI-powered kinase inhibitor platform precisely screens potent and highly selective targets, are you ready?
- Clinical status of standard therapy-resistant & metastatic cancer
- Tracking of popular targets of tumor kinase inhibitors
- RIPK2: a new target for the treatment of inflammatory diseases
- Molecular mechanisms of RIPK2 in promoting tumor progression and drug resistance
- New breakthroughs in the diagnosis & treatment of late-stage metastatic gastrointestinal cancers
- An innovative biotech roadshow
Event details
|
DATE Wednesday, June 25, 2025 VENUE Online Webex / Zoom TIME 8:00 – 9:00 Berlin time (CET) 14:00 – 15:00 Beijing time (GMT+8) RSVP This is a complimentary event VIP tickets priority for Lingmed current clients Please RSVP by June 25, 2025 |
PRESENTERS Lingling Cao, CEO & Founder REGISTER +86 21 5386 3003 info@lingmed.cn |
Agenda
| CET 8:00 - 8:30 | Transforming cancer journeys through disruptive innovations |
by Guest speaker (Chinese) |
| CET 8:30 - 8:35 | Linkedbio services & projects introduction | by Lingling Cao (English) |
| CET 8:35 - 8:55 | An innovative biotech roadshow | by Guest speaker (English) |
| CET 8:55 – 9:00 | Q&A | (English & Chinese) |
Presenters
 |
Lingling Cao CEO & Founder Lingling has more than a decade of experience in the healthcare industry, especially in deal-making. She founded Lingmed, which aims to support BD professionals to make better decisions with intelligence databases and EU-China cross-border deals. Prior to her venture at Lingmed, she was a senior BD manager for Eli Lilly in Shanghai and a consultant for McKinsey in Germany |